(ITV) approach was applied. To evaluate the clinical benefit of DTT, the tumor motion amplitude on 4DCT was compared to the mean maximal peak-to-peak amplitude on fluoroscopy sequences acquired during DTT and the difference in PTV volume (DTT versus ITV) was calculated. Treatment-related toxicity was scored according to the Common Terminology Criteria for Adverse Events v.4.0. Results: A total of 38 lesions were treated in 35 patients. The delivered dose schedules were as follows: 48Gy/4 fractions (n=32), 51Gy/3 fractions (n= 4), 60Gy/8 fractions (n=2). Mean superior-inferior (SI) motion exceeded 8 mm in 14 out of 38 lesions. DTT was used for 7 lesions. Reasons for omitting DTT were: pulmonary function or lesion location not allowing visicoil insertion and history of prior pneumothorax. Mean treatment time for a DTT session was 28.6 minutes (20-34.8 minutes) . Mean SI motion on 4DCT in DTT lesions was 11.8 mm (8.6-16.9 mm). The mean maximal peak-to-peak amplitude observed during fluoroscopy was 20.4 mm (8.2-50.5 mm) demonstraing a significant variability in respiration induced tumor motion. DTT achieved a median reduction of 58% in PTV volume. With a median follow-up of 7 months (3-19 months), 1 local failure was observed in a centrally located lesion treated with an ITV approach. Only 1 patient experienced a grade 2 radiation pneumonitis and 2 patients presented with a COPD exacerbation in the weeks following radiation. No toxicity was observed in the patients treated with DTT. Conclusions: DTT with the Vero4DRT system using a single fiducial marker proved to be clinically feasible and safe. DTT can be performed in an acceptable time frame, is able to account for respiratory variability and results in a substantial reduction in PTV volume.
(1) Matsuo Y, Ueki N, Takayama K, et al. Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac. Radiother Oncol 2014.
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Prediction of normal tissue radiosensitivity from random numbers??? Be cautious out there! C. Andreassen 1 1 Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus C, Denmark Purpose/Objective: Background: During the last decade, several studies have established predictive models for normal tissue radiosensitivity based on multiple SNPs (1-8). Typically, these studies assessed a limited number of SNPs. For some of these SNPs, a 'risk allele' was defined and the studies then looked for an association between the total number of risk alleles and normal tissue complication risk. Even though many of these models have yielded highly significant results, the models have often been inconsistent with each other (table 1) . This probably relates to the way these models were constructed. The process had three steps: 1) For each of the included SNPs, a risk allele (minority vs. majority allele) was defined based on the observation that it was (often non-significantly) associated with the outcome parameter of the study (radiosensitivity). 2) A model was established based on these risk alleles. 3) A statistical test was carried out to determine if the number of risk alleles was significantly associated with radiosensitivity (the same parameter as used for the selection of the risk alleles). By doing so, a circularity is introduced into the analysis that makes it likely that random fluctuations (for the individual SNPs) are amplified into significant associations (for the entire model).
Materials and Methods:
In order to further explore this potential problem, we reanalyzed the dataset originally used to establish the multiple SNP model published by Andreassen et al. in 2003 (1) . Instead of the actual SNP genotypes we randomly assigned 'genotypes' to the patients for 7 fictitious SNPs that had the same relative distribution as the SNPs in the original dataset. Subsequently, we selected risk alleles for these 'SNPs' and established a multiple SNP model exactly as in the original study. This procedure was repeated 10 times. Results: In 8 out of 10 times a significant result was found for the model. This clearly demonstrates that the process of actively fitting the model to the dataset is indeed per se capable of producing nominally significant results for the entire model. Conclusions: Great caution should be taken when a predictive model is established and tested within the same patient cohort. A significant finding for a multiple SNP model established in this way cannot be used to indirectly validate the underlying SNPs. Thus, we have to establish robust associations for the individual SNPs that can be entered into a predictive multiple SNP model that should finally be validated in an independent dataset. (range, . Median DLCO change within one year after RT was 0.81 (range 0.22-1.79). Early DLCO change (3-6 months after RT) had the same range but the median value was 0.77. The genotype distribution of all studied SNPs was: rs189037, 29% AA, 49% AG, 22% GG; and rs228590, 33% CC, 49% CT, 19% TT. Univariate and multivariate analyses showed that the AA genotype of ATM rs189037 was associated with significantly higher DLCO impairment after definitive radiation than the GG/AG genotypes (univariate beta regression coefficient -0.12; 95% confidence interval [CI], -0.24~-0.008; P = 0.037; multivariate beta regression coefficient -0.10; 95% CI, -0.20~-0.005; P = 0.04). However, similar results were not observed for rs228590 (univariate beta regression coefficient -0.10; 95% CI, -0.25~-0.12; P = 0.096).
Conclusions:
The AA genotype of ATM rs189037 was associated with higher risk of lung injury, compared with the GG/AG genotypes in patients with NSCLC treated with radio(chemo)therapy. This response marker may be used for guiding therapy intensity in an individual patient, which would further the goal of individualized therapy. Purpose/Objective: Normal tissue toxicity sets the dose limit for radiotherapy (RT) in cancer treatment and hence has significance for its curative potential. Individual differences in the severity of radiation induced toxicity suggests that there is a possibility of dose escalation to the more radioresistant group. In theory prediction of individual radiosensitivity could augment cure rates of RT. From a previous study we have access to a cohort of 42 prostate cancer patients treated with External Beam RT (EBRT) and clinical data for radiation induced toxicity measured by anal
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